Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 29 04:00PM ET
1.79
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.63 Insider Own2.22% Shs Outstand44.10M Perf Week1.70%
Market Cap79.42M Forward P/E- EPS next Y-0.57 Insider Trans-88.89% Shs Float43.38M Perf Month-66.10%
Income-27.67M PEG- EPS next Q-0.19 Inst Own98.86% Short Float1.67% Perf Quarter-67.98%
Sales0.00M P/S- EPS this Y-13.00% Inst Trans69.58% Short Ratio0.87 Perf Half Y-73.48%
Book/sh2.90 P/B0.62 EPS next Y15.34% ROA-19.33% Short Interest0.73M Perf Year-67.28%
Cash/sh2.95 P/C0.61 EPS next 5Y- ROE-19.83% 52W Range1.40 - 11.67 Perf YTD-72.88%
Dividend Est.- P/FCF- EPS past 5Y25.04% ROI-21.43% 52W High-84.66% Beta1.66
Dividend TTM- Quick Ratio36.95 Sales past 5Y0.00% Gross Margin- 52W Low27.86% ATR (14)0.25
Dividend Ex-Date- Current Ratio36.95 EPS Y/Y TTM-0.58% Oper. Margin0.00% RSI (14)26.32 Volatility3.79% 6.71%
Employees50 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price11.39
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q1.51% Payout- Rel Volume0.06 Prev Close1.79
Sales Surprise- EPS Surprise34.96% Sales Q/Q- EarningsAug 05 BMO Avg Volume835.21K Price1.79
SMA202.61% SMA50-57.88% SMA200-69.86% Trades Volume50,268 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-04-24Downgrade Piper Sandler Overweight → Neutral $15 → $2
Nov-04-24Downgrade Oppenheimer Outperform → Perform
Nov-04-24Downgrade Jefferies Buy → Hold
Jun-26-23Resumed Oppenheimer Outperform $17
Mar-04-21Initiated Piper Sandler Overweight $50
Jan-11-21Reiterated H.C. Wainwright Buy $10 → $17
Nov-02-20Initiated Jefferies Buy $17
Oct-25-19Initiated Oppenheimer Outperform $8
Nov-04-24 08:14AM
Nov-01-24 08:14AM
Oct-31-24 08:57PM
Sep-14-24 09:53PM
Sep-13-24 05:19PM
04:05PM Loading…
Sep-11-24 04:05PM
Aug-05-24 07:03AM
07:00AM
Jul-08-24 04:05PM
May-30-24 08:00AM
May-20-24 07:36AM
May-14-24 01:54PM
07:04AM
07:00AM
Apr-09-24 08:00AM
08:13PM Loading…
Mar-07-24 08:13PM
Feb-26-24 01:14PM
Feb-14-24 04:35AM
Feb-13-24 07:25AM
07:00AM
Feb-07-24 08:47PM
Feb-06-24 08:00AM
Jan-25-24 10:00AM
Dec-21-23 04:13PM
Dec-12-23 12:03PM
09:12AM
07:20AM
07:00AM
Nov-23-23 11:05AM
Nov-21-23 08:00AM
08:00AM Loading…
Nov-08-23 08:00AM
Nov-06-23 05:51PM
Oct-30-23 10:59AM
Oct-26-23 05:41PM
Oct-21-23 09:00AM
Sep-18-23 07:00AM
Aug-31-23 07:00AM
Aug-14-23 08:43AM
Aug-08-23 07:17AM
07:00AM
Jun-06-23 07:00AM
Jun-01-23 07:00AM
May-24-23 11:04AM
May-18-23 06:25AM
May-11-23 07:00AM
May-09-23 07:19AM
07:00AM
Apr-18-23 07:00AM
Apr-12-23 07:00AM
Mar-08-23 07:00AM
Mar-07-23 05:19AM
Feb-23-23 05:43AM
Feb-13-23 05:00PM
Feb-07-23 07:00AM
Feb-02-23 04:01PM
Jan-25-23 05:39AM
Jan-06-23 07:04AM
Dec-21-22 05:07PM
Dec-19-22 08:11AM
Dec-15-22 08:30AM
Dec-13-22 07:00AM
Nov-14-22 09:25AM
Nov-10-22 07:00AM
Oct-31-22 11:13AM
08:58AM
07:00AM
Oct-26-22 04:01PM
07:00AM
Sep-13-22 07:00AM
Aug-10-22 06:40AM
Aug-04-22 07:00AM
Jul-11-22 07:23AM
Jun-30-22 06:21PM
Jun-28-22 06:29AM
Jun-27-22 04:01PM
Jun-02-22 07:00AM
May-27-22 08:12AM
May-10-22 07:00AM
Apr-26-22 04:30PM
Apr-25-22 10:20AM
Apr-08-22 01:00PM
Mar-10-22 04:05PM
Mar-09-22 11:34PM
Mar-08-22 04:30PM
Feb-04-22 05:16AM
Feb-03-22 07:00AM
Jan-19-22 07:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-11-21 05:38AM
Dec-08-21 09:38AM
Nov-22-21 09:20AM
Nov-18-21 07:00AM
Nov-08-21 07:00AM
Oct-28-21 04:05PM
Oct-19-21 01:21PM
Oct-07-21 10:25AM
09:00AM
06:30AM
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH GROWTH N V10% OwnerNov 01 '24Sale1.537,879,58312,018,4090Nov 05 12:06 PM
Virsik PeterChief Operating OfficerOct 07 '24Sale6.036944,1857,776Oct 07 03:00 PM
Virsik PeterChief Operating OfficerSep 09 '24Sale6.006944,1648,470Sep 09 02:03 PM
Virsik PeterChief Operating OfficerSep 03 '24Sale6.032,08212,5549,164Sep 03 06:57 PM
Virsik PeterOfficerSep 03 '24Proposed Sale5.594,16423,277Sep 03 04:17 PM
Virsik PeterChief Operating OfficerMay 06 '24Sale6.956944,82311,246May 06 05:17 PM
Glickman Richard MDirectorApr 24 '24Option Exercise4.903,75018,37543,240Apr 25 10:35 AM
Virsik PeterChief Operating OfficerApr 05 '24Sale7.946945,51011,940Apr 05 06:16 PM
Virsik PeterChief Operating OfficerMar 05 '24Sale8.986946,23212,634Mar 05 06:50 PM
Virsik PeterChief Operating OfficerFeb 06 '24Option Exercise3.2372,782235,08686,110Feb 07 11:29 AM
Virsik PeterChief Operating OfficerFeb 06 '24Sale10.2972,782748,92713,328Feb 07 11:29 AM
Virsik PeterChief Operating OfficerFeb 05 '24Option Exercise3.235001,61513,828Feb 06 08:27 AM
Virsik PeterChief Operating OfficerFeb 05 '24Sale9.581,19411,44013,328Feb 06 08:27 AM
Virsik PeterChief Operating OfficerJan 16 '24Option Exercise3.231,7185,54915,740Jan 17 08:57 PM
Virsik PeterChief Operating OfficerJan 16 '24Sale10.011,71817,19714,022Jan 17 08:57 PM
Virsik PeterChief Operating OfficerJan 05 '24Sale6.116994,27114,022Jan 08 08:06 PM
Parkinson David RossChief Executive OfficerDec 14 '23Buy2.309,22321,21365,675Dec 18 09:57 PM